Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit
- Wednesday, October 27, 2021, 7:13
- PR Newswire
- Add a comment
ATLANTA and BOSTON, Oct. 27, 2021 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced that Dr. Milton Werner, Ph.D.,…
About the Author
admin has written 20771 stories on this site.